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Structural basis for oxygen degradation domain
selectivity of the HIF prolyl hydroxylases
Rasheduzzaman Chowdhury1, Ivanhoe K.H. Leung1,w, Ya-Min Tian2, Martine I. Abboud1, Wei Ge1,
Carmen Domene1,w, Franc¸ois-Xavier Cantrelle3, Isabelle Landrieu3, Adam P. Hardy1, Christopher W. Pugh2, Peter
J. Ratcliffe2,4, Timothy D.W. Claridge1 & Christopher J. Schoﬁeld1
The response to hypoxia in animals involves the expression of multiple genes regulated by the
ab-hypoxia-inducible transcription factors (HIFs). The hypoxia-sensing mechanism involves
oxygen limited hydroxylation of prolyl residues in the N- and C-terminal oxygen-dependent
degradation domains (NODD and CODD) of HIFa isoforms, as catalysed by prolyl hydro-
xylases (PHD 1–3). Prolyl hydroxylation promotes binding of HIFa to the von Hippel–Lindau
protein (VHL)–elongin B/C complex, thus signalling for proteosomal degradation of HIFa. We
reveal that certain PHD2 variants linked to familial erythrocytosis and cancer are highly
selective for CODD or NODD. Crystalline and solution state studies coupled to kinetic and
cellular analyses reveal how wild-type and variant PHDs achieve ODD selectivity via different
dynamic interactions involving loop and C-terminal regions. The results inform on how HIF
target gene selectivity is achieved and will be of use in developing selective PHD inhibitors.
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A
nimals respond to limiting oxygen availability by the
context-dependent upregulation of the expression of
multiple genes as promoted by increased levels of the
a-subunit of the ab-heterodimeric hypoxia-inducible factors
(HIFs). The ferrous iron and 2-oxoglutarate (2OG)-dependent
HIF prolyl hydroxylases (PHDs/EGLNs) catalyse trans-4-prolyl
hydroxylations on HIFa subunits (Fig. 1), thus promoting their
binding to the von Hippel–Lindau protein (VHL), a targeting
component of a ubiquitin E3 ligase, and signalling for HIFa
degradation under normoxic conditions1–5. In hypoxia, HIFa
escapes VHL-mediated degradation, translocates into the nucleus,
where it dimerizes with HIFb to form the functional HIF complex
that activates the transcription of gene arrays. Evidence from both
biochemical and genetic studies support the roles for the PHDs as
the most important identiﬁed hypoxia sensors for the HIF system.
As HIF target genes include those encoding for erythropoietin,
vascular endothelial growth factor and many medicinally
important proteins, therapeutic manipulation of the HIF
system, in particular by PHD inhibition, is of interest. PHD
inhibitors are in clinical trials for anaemia treatment via
HIF-mediated erythropoietin upregulation6,7, although these
inhibitors are not PHD isoform selective.
Bioinformatics imply that the HIF–PHD–VHL triad-based
hypoxia-sensing system is likely to be present in almost all
animals, but not in other eukaryotes8,9. In early animals (that is,
those that emerged before the whole genome duplications), there
is normally one copy of the PHDs and one of HIFa with only one
HIFa hydroxylation site. However, concomitant with the
evolution of complex animals and associated whole genome
duplications, animals with multiple copies of HIFa/PHDs
emerged. The increases in the complexity of the HIF system
probably reﬂect the needs for more sophisticated hypoxia
response mechanisms involving the complex cardiovascular
systems present in higher animals. Humans have three HIFa
isoforms (with HIF-1a/-2a being the best characterized)
and three PHDs. The PHD-catalysed hydroxylations of
HIF-1a/HIF-2a in higher animals occur in amino- and
carboxy-terminal oxygen-dependent degradation domains
(NODD and CODD)10–12. Non-HIF substrates for the PHDs
have been reported but the physiological signiﬁcance of these in
the hypoxic response is presently unclear (for review, see ref. 13).
Different roles for the PHDs and HIFa isoforms including for
their ODDs are emerging. NODD hydroxylation is more sensitive
to hypoxia than CODD14,15. The three human PHDs exhibit
different NODD/CODD selectivities, with PHD3 being substan-
tially more selective for CODD than PHD1/2 (refs 16,17 and
Supplementary Fig. 1). Some clinically observed heterozygous
mutations to PHD2 (which genetic studies have revealed is
indispensable in mice18–20, unlike PHD1 and PHD3), stabilize
HIFa and cause familial erythrocytosis21 or are linked to
cancer22. We found that certain PHD2 variants linked to
familial erythrocytosis and cancer are highly selective for
CODD or NODD. We therefore worked to obtain structural
information on how the different ODDs bind to the PHDs,
focusing on PHD2. Here we report studies on the molecular basis
for ODD selectivity of the wild-type (wt) and variant PHDs.
Results
PHD2 clinical variants are selective for CODD or NODD.
Analysis of a PHD2.N-oxalyl glycine (NOG).CODD complex
structure23 led us to propose that certain erythrocytosis-
associated PHD2 variants (P317R24,25 and R371H26) would
have altered substrate selectivities (Fig. 2a). Indeed, recombinant
P317R PHD2 retains full CODD activity compared with wt
PHD2, but strikingly does not hydroxylate NODD (Fig. 2b),
suggesting its phenotype could be associated with loss of NODD
hydroxylation. R371H PHD2 retains 460% NODD activity and
is equally active as wt PHD2 with CODD in endpoint assays
(Supplementary Tables 1 and 2); kinetic analyses show R371H is
less efﬁcient compared with wt PHD2 (for R371H, kcat/Km is
reduced by B50% for NODD and CODD; Fig. 2b). A PHD2
R396T variant, present in breast carcinoma27, and an R396A
variant efﬁciently hydroxylate NODD, but both manifest loss of
CODD activity (Fig. 2b). To investigate their selectivities in cells,
the PHD2 variants were expressed in mouse embryonic
ﬁbroblasts (MEFs) lacking all three PHDs (‘triple knockout’/
TKO MEFs deﬁcient in HIF hydroxylation). Using hydroxy-
NODD/CODD-speciﬁc antibodies15, we observed high NODD/
CODD selectivities for the variants consistent with the isolated
protein results (Fig. 2d); both sites were efﬁciently hydroxylated
with wt PHD2.
We then investigated the structural basis of the striking
differences in the NODD/CODD selectivities of the clinical
PHD2 variants. Structures of the P317R, R371H and R396T
variants with a clinically used inhibitor6,28 reveal similar
overall folds to wt PHD2, that is, a modiﬁed double-stranded-
b-helix (DSBH) core (b-strands I–VIII), supporting 2OG and
Pro
HIF-α HIF-α HIF-α
HIF-β
O2
HIF-α
degradation
NODD CODD Hypoxia
OH
ProPro
HIF-α O2
NODD CODD
OH OH
NODD CODD
N
H H
O
PHD1/2 PHD3PHD1/2
N
OH
HO
2OG
O2
Succinate
CO2
ProProPro
Selective upregulation
of HIF target genes
CODD CADbHLH PAS-A NODDPAS-BN C
O2
OHOH
HIF-α 
stabilization
HIF-α prolyl
hydroxylation
Dimerization/ DNA binding
~2.0% ~0.5%
PHD 1–3
Fe(II)
HIF-αHIF-α
(C4 exo) (C4 endo)
Figure 1 | Overview of the HIF system. The ﬁgure shows the roles of HIFa NODD/CODD hydroxylation in the hypoxic response. Ordered ODD
hydroxylation is tightly regulated in animals; NODD hydroxylation is more sensitive than CODD to hypoxia14,15. ODD hydroxylation signiﬁcantly increases
the afﬁnity of hydroxylated HIFa for the VCB (VHL, elongins B and C) complex, thus signalling for HIFa degradation via proteosomal hydrolysis; the
difference in kd for hydroxylated versus non-hydroxylated CODD is B1,000-fold (33 nM versus 34 mM, respectively)34. In response to hypoxia, HIFa
escapes ODD hydroxylation and forms the ab-heterodimeric HIF complex that activates the transcription of a gene array.
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His-X-AspyHis-mediated Fe(II) binding. The structures
suggested that these variants probably manifest altered substrate
binding (Fig. 2e–g), but do not explain how their differing
NODD/CODD selectivities arise. The PHD2.NOG.CODD
structure reveals elements involved in CODD binding including
a ‘b2/b3 loop’23,29 but there is no information on the details of
NODD binding, nor on how ODD selectivity is achieved. We
therefore pursued biophysical and biochemical analyses on
PHD2.NODD complexes.
PHD2.ODD complexes reveal insights into ODD selectivities.
We obtained a PHD2.2OG.CODD structure using the strategy
used for the PHD2.NOG.CODD complex23, but did not obtain
PHD2.NODD crystals using this procedure, possibly because
NODD binds PHD2 less tightly, as indicated by a lower
dissociation rate constant (kd) for CODD compared with
NODD29. We then used a ‘disulﬁde cross-linking’ strategy30,31
to form stable PHD2.Mn.NOG.NODD complexes, where
PHD2QM1 (C201A/P317C/R281C/R398A) or PHD2QM2 (C201A/
V314C/R281C/R398A) and NODDDC (L397C/D412C) are cross-
linked via appropriately positioned cysteines (Supplementary
Fig. 2). Molecular dynamics (MD) simulations predict the
PHD2.Fe.2OG.NODD solution structure is very similar to that
of the disulﬁde-linked complex, PHD2QM1.Mn.NOG.NODDDC
(or PHD2.NODD) (Supplementary Fig. 3).
Both ODDs bind to PHD2 in an extended form (Ca root mean
square deviation (r.m.s.d.), CODD558–574/NODD396–412, 2.4 Å)
with several bends and an N-terminal 310-helix containing the
HIFa LXXLAP3,5 motif. The target prolines (P402/NODD and
P564/CODD, both in C4 endo conformation32) are located at the
apexes of the bends and, similar to metal and 2OG, are deeply
embedded in the active site (Fig. 3). Comparison of the ODD
complex structures and those without substrate reveals clear
differences in NODD/CODD binding, especially in b2/b3 loop
and C-terminal regions (Fig. 4).
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Figure 2 | Clinically observed variants in PHD2 have altered selectivities. (a) View from the PHD2.CODD complex (PDB: 3HQR) showing locations of
PHD2 clinical variants with altered ODD selectivities. (b) Kinetic analyses show the P317R and R396X variants are highly selective for CODD and NODD,
respectively; R371H is less efﬁcient at the same CODD/NODD activity ratio (10:3) as wt PHD2 with (almost) unaltered selectivity. kcat/Km values are
calculated from the average kcat and Km values (Supplementary Table 3). (c) One-dimensional
13C-selective clean in-phase (CLIP)–HSQC NMR reveals
apparently selective displacement of NODD/CODD from PHD2 wt/clinical variant complexes by using PHD inhibitors (FG2216/ FG4592) (Supplementary
Fig. 13). n¼ 5 for wt and 2 for variants. (d) Selectivity studies using hydroxy-proline antibodies (NODD-OH and CODD-OH) and PHD 1–3 TKO MEF cells.
MG 132 was used to block proteasomal degradation. In TKO cells, HIF-1a is not hydroxylated (lane 1); both NODD/CODD are fully hydroxylated in cells
expressing wt PHD2 (lanes 3 and 5). Highly selective NODD/CODD hydroxylation is observed with variant PHDs irrespective of expression level of the
Flag-tagged proteins. (e,f,g) Views from PHD2 P317R, R371H and R396T crystal structures superimposed with PHD2.CODD complex, suggesting
substantial impact of the substitutions on substrate binding.
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Binding of residues N-terminal to target prolines involves the
DSBH bII, bII–III loop, b2/b3 loop, bVI–VII loop, bVIII and bIII
regions (Supplementary Fig. 4). Excepting the b2/b3 loop, these
elements are well-conserved in animal PHDs. Notably, b2/b3
loop residues (Val241, Ser242, Lys244 and Ile251) interact with
the ‘XX’ residues of the LXXLAP motif, which differ in
NODD and CODD (Glu560/Met561CODD; Thr398/Leu399NODD)
(Supplementary Fig. 4). Substitution of b2/b3 loop Val241,
Ser242, Lys244 and Ile251 residues to Ala, Gly, Arg and Leu,
respectively, as present in the CODD-selective PHD isoform,
PHD3 (Ala62PHD3, Gly63PHD3, Arg65PHD3 and Leu73PHD3)
causes increased CODD selectivity, revealing speciﬁc b2/b3
elements contributing to selectivity (Fig. 5).
Binding of ODD residues C-terminal of the target prolines
involves DSBH bVIII, bIII, helix a3 and the a3-bI loop
(Supplementary Fig. 5). In addition, CODD, but not NODD,
interacts with a4 including via salt-bridging (Asp571CODD–
Arg396PHD2). NODD makes more hydrophobic contacts than
CODD with the C-terminal region of PHD2 (Supplementary
Fig. 5). Using biochemical and structural studies, we identiﬁed
four more residues in a3 and a3-bI loop regions (PHD2/Ile280,
Arg281, Ile292 and Gly294 that are substituted in PHD3/Val102,
Leu103, Val114 and Glu116, respectively) and which play roles in
determining selectivity (Fig. 5 and Supplementary Figs 6 and 7).
NMR analyses of PHD2 interactions with ODDs. We then used
nuclear magnetic resonance (NMR) to investigate whether the
crystallographically observed differences in ODD binding apply
in solution. We ﬁrst assigned backbone resonances of
PHD2.Zn.2OG with and without CODD (using ZnII as an FeII
substitute, Supplementary Fig. 8). Consistent with the crystal-
lographic results, large chemical shift perturbations manifested at
the PHD2.CODD binding interface including in the b2/b3 loop
region and a4 (Fig. 6a–e); 15N relaxation and heteronuclear NOE
measurements reveal the dynamic nature of these regions,
particularly the b2/b3 loop (Fig. 6d). Notably, the plasticity of the
b2/b3 loop is substantially reduced on substrate binding (430%
with CODD as manifested by comparing the relative changes in
the 15N T2 and 1H-15N NOE values between the PHD2. 2OG and
PHD2.2OG.CODD complexes), revealing a role for the b2/b3
loop in stabilizing the PHD2.ODD complexes.
Similar to CODD, when NODD was titrated into labelled
PHD2.Zn.2OG, chemical shift perturbations were observed at the
binding interface, including in the b2/b3 loop (Fig. 6c). However,
an important difference between NODD and CODD binding is
that in contrast to CODD, substantially less perturbation was
observed in the helix a4 with NODD (Fig. 6b,c and e), supporting
the crystallography, that is, a4 adopts similar conformations
whether bound to NODD or not (Fig. 4). To investigate NODD
binding, we also used competition experiments with [13C]-
labelled NODD and unlabelled CODD, and with [13C]-labelled
CODD and unlabelled NODD. Consistent with the crystal-
lographic analyses, the results reveal that CODD and NODD bind
competitively with each other to PHD2.Zn.2OG with a clear
preference for CODD (Fig. 6f).
CODD-selective residues are conserved during PHD evolution.
To investigate how ODD binding relates to selectivity, we pro-
duced PHD3 variants aimed at increasing the NODD activity of
PHD3: R65K and L73I PHD3 variants manifest increased NODD
hydroxylation relative to wt PHD3 (Supplementary Fig. 9). We
also investigated conservation of PHD2 residues other than the
clinical variants (see below) involved in selectivity (that is, Ser242,
Lys244, Ile251, Ile280, Arg281, Ile292 and Gly294 residues) using
structurally informed bioinformatics on animal PHDs; except for
Ile251PHD2 (which is often a Leu as in PHD3), none of these
residues are well conserved. Notably, kinetic studies reveal PHD2
I251L is remarkably (B5-fold) selective for CODD over NODD
(Fig. 5c), indicating there is a preference for conservation of
CODD-selective residues during PHD evolution (see below).
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Structural analyses rationalize PHD2 variant selectivities.
Comparison of the structures rationalizes the selectivities of the
clinically observed P317R, R371H and R396T variants.
Pro317PHD2 (bII-III loop) forms part of a hydrophobic patch
binding the ODD LXXLAP-310-helix. The P317R structure
reveals Arg317PHD2 present in two conformations, one predicted
to interact differently with the LXXLAP motif (Supplementary
Fig. 10). The lack of reactivity of P317R PHD2 with NODD
supports a relatively more important role for Pro317PHD2 in
binding the LXXLAP residues in NODD than CODD.
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Arg371PHD2 (bVI-VII loop) apparently positions the
Arg370PHD2 side chain in ODD binding (Supplementary Fig. 11):
Arg370PHD2 interacts with both Asp395NODD (electrostatic)
and Leu559CODD (hydrophobic); substitution of Arg370PHD2
with alanine did not affect CODD hydroxylation, but gaveB35%
reduction in NODD activity, demonstrating Arg370–Arg371 is
more important in NODD than in CODD hydroxylation.
In the PHD2.CODD structure, Arg396PHD2 (a4) is positioned
to salt bridge with Asp571CODD; analysis of the ODD structures
leads to the prediction that the R396T and R396A substitutions
disrupt their interaction with Asp571CODD, but will not
directly have an impact on NODD binding (Fig. 2g). Indeed,
structures of R396T with/without NODD indicate how
R396T substitution is tolerated for NODD binding (Supple-
mentary Fig. 12). Interestingly, Asp571CODD is also impo-
rtant in VHL–HIFa binding, where it salt bridges with
Arg107VHL33,34; the high conservation of Arg396PHD2 and
Arg107VHL implies that both these interactions are important
in PHD–VHL evolution8.
PHD clinical inhibitors differently displace NODD or CODD.
The revelation of differential contributions from speciﬁc PHD
regions in ODD binding raises the possibility of identifying inhi-
bitors that compete differently with NODD or CODD. Indeed, we
found that FG2216 (IOX3)35, used in clinical trials for treatment of
anaemia, preferentially displaces NODD over CODD from PHD2
(Fig. 2c). Analysis of PHD2.FG2216 complex structures, with and
without CODD (PDB: 3HQU, 4BQX), suggests this is because of
the relatively greater role of the LXXLAP region in NODD
compared with CODD binding (with CODD, loss of LXXLAP
binding is compensated by interactions involving C-terminal
regions). In contrast, FG4592 (Roxadustat)35, a newer compound
in clinical trials36, efﬁciently displaces both CODD and NODD
from PHD2 likely to be due to its phenoxy group, which projects
into regions binding the residues C-terminal to the hydroxylated
prolines of both ODDs (Supplementary Fig. 13). Notably, the
selectivity of NODD/CODD displacement by the inhibitors differs
for the R396T and P317R variants compared with wt PHD2. In the
case of R396T (which does not hydroxylate CODD efﬁciently, 2b),
both FG2216 and FG4592 manifest NODD displacement less than
wt PHD2 (Fig. 2c). P317R (which does not hydroxylate NODD,
2b) differs in that both inhibitors displace CODD too10%, which
is also less than for wt (with FG4592). These results imply
development of inhibitors differentially blocking NODD versus
CODD binding should be possible.
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Figure 6 | NMR studies reveal dynamics of ODD selectivity determinants in solution. Surface representations of PHD2.CODD (CODD in grey, PDB:
5L9B) (a) and PHD2.NODD (NODD in yellow, PDB: 5L9V) (b) showing perturbed regions (colour coded) on ODD binding with differences in chemical shift
values in c. On CODD binding, changes concentrate in: N terminus (a1, aa 190–195; a2, 229–231; b2/b3 loop, 234–254; b4, 255–258; and a3-bI, 294–298),
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Compared with CODD, binding of NODD induces fewer changes including in: b2/b3 loop (236–241 and 247–255), b4 (257–258), b4-a3 (259–262), a3
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Discussion
PHD variant-associated erythrocytosis has been near exclusively
linked to PHD2 (ref. 21). Our ﬁnding that certain clinically
observed PHD2 mutations substantially alter ODD selectivity,
that is, the erythrocytosis-associated P317R PHD2 (refs 24,25)
variant towards CODD, and the breast cancer-associated R396T
PHD2 (ref. 27) variant towards NODD, implies that altered
PHD2 selectivity may have pathological consequences.
Biophysical analyses employing crystallography and NMR
reveal that the molecular basis of PHD isoform and variant
selectivity involves enzyme–substrate interactions involving
b2/b3 loop residues (that bind the LXXLAP motif) and helices
a3 and a4, regions which display sequence variations between the
PHD isoforms. The results reveal higher conservation of residues
correlating with maintenance of CODD over NODD selectivity
during the course of animal evolution that ‘CODD-type’
hydroxylation probably evolved before that of NODD8, the
greater importance of induced ﬁt in CODD compared with
NODD binding and clinical/genetic evidence that loss of wt
PHD2 cannot be compensated for by PHD 1/3 (refs 19,20,37–39).
The identiﬁcation of speciﬁc interactions determining PHD
selectivity for ODDs opens the way forward to PHD isoform and
ODD selective inhibitors, which may be useful for the
upregulation of speciﬁc sets of HIF target genes. The
identiﬁcation of the features determining HIFa ODD selectivity
should also be of interest with respect to validating reports of
non-HIF substrates for the PHDs.
Methods
Materials. Chemicals were from Sigma-Aldrich, Merck Chemicals and Alfa Aesar.
Isotopically labelled compounds for NMR were from Apollo Scientiﬁc (Stockport,
UK), Cambridge Isotope Laboratories (Tewksbury, MA, USA), Cortecnet (Voisins-
Le-Bretonneux, France) or Euriso-Top (Paris, France). Matrix-assisted laser
desorption/ionization–time of ﬂight matrices, matrix buffers and calibrants were
from LaserBio Labs (Valbonne, France), HIF-1a NODD395–413 and HIF-1a
CODD556–574 peptide substrates (C-terminal amides) were from GL Biochem
(Shanghai, China) and DNA primers were from Sigma Genosys.
Recombinant protein production. DNA sequences encoding human PHD3 and
truncated PHD2181–426 (PHD2) were cloned into pET-28a(þ )/pET-24a(þ ) by
using restriction enzymes NheI/ BamHI, to enable production of proteins with/
without an N-terminal His6 tag23. The His6 tags were removed by proteolysis using
thrombin, which leaves a ﬂanking sequence of GSHMAS, N terminus to the PHD2
wt and variant sequences. The PHD2 and PHD3 variants were prepared using
site-directed mutagenesis (Stratagene). For the production of isotopically labelled
PHD2, a construct encoding for PHD2181–402 was cloned into the pET-28a(þ )
vector. All constructs were veriﬁed by DNA sequencing.
PHD2, PHD3 and their variants were produced in Escherichia coli BL21(DE3)
cells by induction with 0.5mM isopropyl b-D-1-thiogalactopyranoside for 4–6 h at
28 C/37 C. Cells were freeze–thawed and lysed in 20mM Tris HCl pH 7.0–7.5,
0.5M NaCl and 5% glycerol (or alternatively in 0.1M MES Na pH 5.8) by
sonication. Proteins were puriﬁed by Ni2þ afﬁnity (tetracarboxymethyl
ethylenediamine) or by cation-exchange (SP Sepharose Fast Flow, GE Healthcare)
chromatography followed by size-exclusion chromatography (0.1M Tris HCl pH
7.5, 0.1M NaCl/PHD2 and 50mM Tris?HCl pH 7.5, 0.5M NaCl, 5% glycerol and
0.5mM tris(2-carboxyethyl)phosphine/PHD3). PHD2 wt and variants were
exchanged into 50mM Tris HCl buffer pH 7.5 and stored at 25–30mgml 1.
PHD3 proteins were buffer exchanged into 50mM Tris?HCl pH 7.5, 0.5M NaCl,
5% glycerol and 0.5mM tris(2-carboxyethyl)phosphine (TCEP) and stored at
2–5mgml 1. Protein purity was assessed by SDS–PAGE; proteins were
characterized by electrospray ionization mass spectrometric analyses under
non-denaturing and/or denaturing conditions.
Isotopically labelled PHD2181–402 was produced in E. coli BL21(DE3). Cells were
grown at 37/30 C (to an OD600 of 0.6–1.0) either in 600ml of M9 minimal
media supplemented with 1 g l 1 of 15N-labelled NH4Cl and 10 g l 1 D-glucose
(for 15N-labelled PHD2181–402) or in 600ml of M9 minimal media in D2O
supplemented with 1 g l 1 of 15N-labelled NH4Cl and 4 g l 1 of 2H,13C-labelled
D-glucose (for 2H,13C,15N-labelled PHD2181–402). Protein production was induced
with 0.2mM isopropyl b-D-1-thiogalactopyranoside (overnight, 28/18 C). Cells
were resuspended and lysed in buffer containing 50mM Hepes-Na, 0.5M NaCl
and 5mM imidazole (pH 7.8). The labelled proteins were puriﬁed by gravity-ﬂow
Ni2þ afﬁnity (nitrilotriacetic acid) chromatography. Apo-PHD2181–402 was
produced by incubation (at 1mgml 1 protein concentration) with EDTA (0.2M)
in 15mM ammonium acetate (pH 7.5) overnight at 4 C. Protein purity was
assessed by SDS–PAGE. The puriﬁed proteins were stored in 50mM Tris-D11 pH
6.6 and 0.02% NaN3 at  80 C.
Enzyme assays. 2OG turnover was measured by assaying [14C]-CO2 produc-
tion23. Peptide hydroxylation was measured by matrix-assisted laser desorption/
ionization–time of ﬂight mass spectrometry with appropriate controls23. For initial
velocity measurements, assays were carried out using at least two optimum time
points (where the initial rate was linear) over a range of substrate concentrations
(5–150 mM). Data were analysed using Graphpad Prism 5 for ﬁtting into
Michaelis–Menten equation that enabled kinetic parameters, Km (or apparent Km)
and kcat to be determined by using nonlinear regression, least squares ﬁtting±95%
conﬁdence intervals. kcat/Km values are calculated from the mean kcat and Km
values for wt and variant enzymes.
Cell-based studies. The effects of PHD variants on HIF hydroxylation were
assayed in cells with a PHD-null background using hydroxy-proline-speciﬁc
antibodies15. The TKO PHD1–3 null MEFs (TKO MEFs) were generated from
Phd1 / ; Phd2ﬂ/ ; Phd3 / embryos derived by appropriate mouse
intercrosses, followed by inactivation of the remaining Phd2 allele by adenovirus
expressed Cre-recombinase in cell culture40. Before further experiments, the TKO
MEFs were validated to manifest lack of HIF-1a prolyl hydroxylation by
immunoblotting using hydroxylation site-speciﬁc antibodies as previously
described15. Constructs encoding for 3 Flag-tagged PHD2 in pcDNA3 were used
to generate NODD/CODD-selective variants (S242G, R281L, P317R, R396T and
R396A) by site-directed mutagenesis (Promega) and subcloned into pRRL lentiviral
vector. PHD2 virus were produced in 293T cells by transient transfection for 48 h.
Wt and variant PHD2 were re-expressed in the TKO MEFs by viral infection for
44 h, followed by 4 h incubation with 25 mM MG 132, to block proteasomal
degradation; this procedure enabled accumulation and simultaneous measurement
of both hydroxylated CODD and NODD even in the presence of oxygen. The cells
were then lysed in urea/SDS buffer (6.7M urea, 10mM Tris-HCl pH 6.8, 10%
glycerol, 1% SDS and 1mM dithiothreitol). Hydroxylation of HIF-1a was analysed
by immunoblotting that employed antibodies speciﬁc for mouse HIF1a hydroxy
prolines for both NODD (Hyp402) and CODD (Hyp577 analogous to Hyp564 in
human HIF-1a) sites.
NMR analyses. Data collection and sample details are given in Supplementary
Table 4. Triple resonance experiments including HNCO, HN(CA)CO,
HN(CO)CA, HNCA, HN(CO)CACB and HNCACB were conducted for PHD2
backbone assignment. Overall, 86% of backbone amide signals (excluding prolines)
were assigned for 2H,13C,15N-PHD2181–402.Zn(II).2OG and 81% (excluding pro-
lines) for 2H,13C,15N-PHD2181–402.Zn(II).2OG.CODD. Owing to the limited
NODD solubility, triple resonance experiments were not performed with
2H,13C,15N-PHD2181–402.Zn(II).2OG.NODD.
Changes in amide chemical shifts (Dd, in p.p.m.) between 2H,13C,15N-
PHD2181–402.Zn(II).2OG and 2H,13C,15N-PHD2181–402.Zn(II).2OG.CODD were
measured using the formula41: Dd ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðDd1HÞ2 þðDd15N10 Þ2
q
. For PHD2 residues not
assigned in CODD bound and/or unbound complexes, Dd were deﬁned as 0 p.p.m.
In cases where multiple peaks were assigned to the same residues, only the main
peaks were considered for Dd measurements. To measure the chemical shift
perturbation on NODD binding, 15N-HSQC spectra were recorded on the
15N-PHD2.Zn(II).2OG.NODD complex (Supplementary Table 4). The ‘transfer’ of
assignments for 1H and 15N chemical shifts between 2H,13C,15N-labelled and
15N-labelled proteins was carried out manually. Backbone amides for 2H,13C,
15N-PHD2181–402.Zn(II).2OG.NODD were not assigned. Instead, the minimal shift
assumption42,43, in which residues involved in NODD binding were mapped to the
closest neighbouring peak, was applied for measuring the chemical shift changes.
15N relaxation (T1 and T2) and heteronuclear NOE experiments were carried
out to investigate PHD2 dynamics (Supplementary Table 4). Ten delays were used
for T1 measurements (0.02, 0.1, 0.2, 0.3, 0.4, 0.6, 0.7, 0.8, 1.0 and 1.5 s) and 11
delays for T2 measurements (4.24, 8.48, 16.96, 21.2, 25.44, 33.92, 42.4, 59.36, 76.32,
93.28 and 110.24ms).
The clean in-phase–heteronuclear single-quantum correlation (HSQC)
sequence was used in one-dimensional HSQC experiments without 13C decoupling
for displacement measurements. Typical experimental
parameters were as follows: acquisition time, 0.58 s; relaxation delay, 2 s; and
number of transients, 256 1,600. The 1JCH delay was set for 145 or 160Hz. A
6.8ms Q3 180 pulse was used and 13C selective irradiation was applied at
30.5 p.p.m. (2OG C-4) or 24.65 p.p.m. (proline C-4). The percentage displacement
was measured based on the integrated area observed on addition of a competitor. A
100% displacement corresponds to a peak intensity similar to the one observed
with the free label control, in the absence of protein. Percentage displacement was
calculated according to equation: (I–I0)/(Iblank–I0) where I0 is the intensity of the
reporter in the presence of protein without inhibitor, I is the intensity of the
reporter in the presence of protein and inhibitor, and Iblank is the intensity of the
reporter without protein or inhibitor. 13C-2OG was labelled at carbon positions 1,
2, 3 and 4, and 13C-CODD/NODD was uniformly labelled at all carbon atoms of its
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proline ring. Solutions were buffered using Tris-D11 50mM (pH 7.5) dissolved in
H2O-D2O (9:1). Assays were conducted at 298K in solutions typically containing
50mM apo-PHD2, 400mM Zn(II), 50 mM labelled 2OG or CODD/NODD (where
appropriate) and 800mM competitor.
Crystallography. PHD2 wt/variant complex crystals were grown as described in
Supplementary Table 5. In general, crystals were cryoprotected by transferring to a
solution of mother liquor supplemented with 25–30% (v/v) glycerol before being
cryo-cooled in liquid N2. As described in Supplementary Tables 6–8, data were
collected at 100K using synchrotron radiation at the Diamond Light Source
beamlines. Data were processed as outlined in Supplementary Tables 6–8.
Structures were solved by molecular replacement using PHASER44 (search
model PDB ID 4BQX or 3HQR) and reﬁned by alternative cycles of PHENIX45,
CNS46 and BUSTER47 using the maximum-likelihood function and bulk-solvent
modelling. Iterative cycles of model building in COOT48 and reﬁnement proceeded
until the Rcryst/Rfree values converged. Final rounds of reﬁnement were performed
by PHENIX45. MOLPROBITY49 were used to monitor the geometric quality of the
models between reﬁnement cycles and identify poorly modelled areas needing
attention. Water molecules were added to peaks 41.8s in 2Fo–Fc electron density
maps that were within hydrogen bonding distance to protein with reasonable
hydrogen bonding geometry.
MD simulations studies. Models for PHD2.Fe.2OG.HIF-1aNODD395–412,
PHD3.Fe.2OG.HIF-1aNODD395–412 and PHD3.Fe.2OG.HIF-1aCODD558–574 were
generated using crystal structures of PHD2QM1.Mn.NOG.HIF-1aNODDDC(395–413)
(or PHD2.NODD) and PHD2.Mn.2OG.HIF-1aCODD558–574 (or PHD2.CODD) as
templates in the automodel feature of MODELLER v8.1 (ref. 50). The substrate–
complex crystal structures as well as the above models were analysed. Acetyl groups
were added to the N-termini of PHD2/substrate peptides and the C-termini were
amidated.
All residues were in their default protonation states; H atoms were added using
the software psfgen of VMD2.6. Histidines were protonated at the delta position.
All crystallographic waters were included in models. Systems were solvated with a
box padding of 18 18 18Å3 dimension. Counter-ions were added where
appropriate, to achieve neutrality of the simulation systems. The drift from an
initial model was used as a measure of the relative ‘stability’ of a given structure in a
simulation. The drift was measured as the time-dependent Ca atom r.m.s.d. from
the initial model. The initial rise in Ca r.m.s.d. in the ﬁrst 0.2–0.3 ns is common in
such simulations and has been attributed to relaxation of the protein on its transfer
to the solution environment and/or inaccuracies in the potential function.
MD simulations were performed using NAMD2.6 (ref. 51) and the
CHARMM-22 all atom force ﬁeld with CMAP corrections52 with the TIP3P model
for waters53. A set of force ﬁeld parameters for 2OG and NOG were developed.
Standardized protocols based on the original development of the force ﬁeld were
followed, to ensure the transferability of the parameters. A 1 fs time step was used
to integrate the equations of motion. Coordinates were saved every 1 ps. Long-
range electrostatic interactions were treated by the particle mesh Ewald
algorithm54; a 10Å cutoff was used for van der Waals interactions. Langevin
dynamics controlled the temperature at 25 C, with a damping factor of 5 ps 1.
The Nose´–Hoover Langevin pressure control55,56 was used to maintain a pressure
of 1 bar (piston period was 200 fs and the damping time scale was 100 fs). Energy
was ﬁrst minimized by a steepest descent procedure (10,000 steps), followed by
production runs of 6 to 15 ns of unconstrained dynamics in the NpT ensemble.
Overall, this corresponds to a total simulation time of 122 ns. Each system was
composed of B60,000 atoms.
Statistical analysis. Each endpoint assay results are the mean of three indepen-
dent experiments with error bars representing the s.e.m. For kinetic measurements,
each experiment was carried out (at least) in technical triplicate (n¼ 3–9). Two
independent biological replicates were done for the results in Figs 2d and 5d.
Data availability. Atomic coordinates and structure factors for the crystal struc-
tures are deposited in the protein databank under the accession numbers 5L9R,
5L9B, 5L9V, 5LA9, 5LAS, 5LAT, 5LB6, 5LBB, 5LBC, 5LBE and 5LBF. Chemical
shifts of the 2H,13C,15N-PHD2.Zn(II).2OG and 2H,13C,15N-PHD2.Zn(II).2OG.-
CODD have been deposited in the Biological Magnetic Resonance Data Bank
under accession codes 26741 and 26742, respectively. The additional data that
support the ﬁndings of this study are available from the corresponding author
upon request.
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